

What is claimed is:

1. A method of treating a mammal having edema comprising administering to said mammal an effective amount of hVEGF antagonist.
- 5 2. The method of claim 1 wherein said edema comprises cerebral edema.
3. The method of claim 1 wherein said mammal is a human further having a neoplastic disease.
- 10 4. The method of claim 3 wherein said neoplastic disease comprises a brain tumor.
5. The method of claim 4 wherein said hVEGF antagonist is administered to said mammal serially or in combination with chemotherapy or radiation
15 therapy.
6. The method of claim 1 wherein said mammal is a human further having or having undergone a stroke.
- 20 7. The method of claim 1 wherein said hVEGF antagonist comprises an anti-hVEGF antibody.
8. The method of claim 7 wherein said anti-hVEGF antibody comprises a chimeric antibody.
25
9. The method of claim 7 wherein said anti-hVEGF antibody comprises a humanized antibody.
10. The method of claim 7 wherein said antibody comprises a monoclonal
30 antibody.
11. The method of claim 1 wherein said hVEGF antagonist comprises a hVEGF receptor fusion protein.
- 35 12. The method of claim 11 wherein said hVEGF receptor fusion protein comprises an extracellular domain sequence of a hVEGF receptor fused to an immunoglobulin.

13. The method of claim 12 wherein said hVEGF receptor fusion protein comprises a flt-IgG fusion protein.

14. A method of treating a mammal having or having undergone a stroke,
5 comprising administering to said mammal an effective amount of hVEGF antagonist.

15. The method of claim 14 wherein said hVEGF antagonist comprises an anti-hVEGF antibody.
10

16. The method of claim 15 wherein said anti-hVEGF antibody comprises a chimeric antibody.

17. The method of claim 15 wherein said anti-hVEGF antibody comprises a
15 humanized antibody.

18. The method of claim 15 wherein said antibody comprises a monoclonal antibody.

19. The method of claim 14 wherein said hVEGF antagonist comprises a hVEGF
20 receptor fusion protein.

20. The method of claim 19 wherein said hVEGF receptor fusion protein
comprises an extracellular domain sequence of a hVEGF receptor fused to an
25 immunoglobulin.

21. The method of claim 20 wherein said hVEGF receptor fusion protein
comprises a flt-IgG fusion protein.
30

22. A method of treating a mammal having cerebral edema comprising
administering to said mammal an effective amount of hVEGF antagonist.

23. The method of claim 22 wherein said hVEGF antagonist comprises an anti-hVEGF antibody.
35

24. The method of claim 23 wherein said anti-hVEGF antibody comprises a chimeric antibody.

25. The method of claim 23 wherein said anti-hVEGF antibody comprises a humanized antibody.

5 26. The method of claim 23 wherein said antibody comprises a monoclonal antibody.

27. The method of claim 22 wherein said hVEGF antagonist comprises a hVEGF receptor fusion protein.

10

28. The method of claim 27 wherein said hVEGF receptor fusion protein comprises an extracellular domain sequence of a hVEGF receptor fused to an immunoglobulin.

15 29. The method of claim 28 wherein said hVEGF receptor fusion protein comprises a flt-IgG fusion protein.

20